鱼跃医疗
(002223)
| 流通市值：334.92亿 | | | 总市值：357.68亿 |
| 流通股本：9.39亿 | | | 总股本：10.02亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,027,852,090.96 | 4,307,611,897.68 | 2,231,209,294.86 | 7,971,734,452.47 |
| 营业收入 | 6,027,852,090.96 | 4,307,611,897.68 | 2,231,209,294.86 | 7,971,734,452.47 |
| 二、营业总成本 | 4,578,931,808.83 | 3,182,191,111.21 | 1,584,225,003.71 | 5,804,425,624.49 |
| 营业成本 | 3,005,841,561.23 | 2,151,188,718.65 | 1,116,936,863.37 | 3,866,870,037.23 |
| 税金及附加 | 58,577,803.51 | 41,054,467.23 | 22,470,746.66 | 81,308,688.83 |
| 销售费用 | 930,620,028.23 | 613,852,772.29 | 273,563,568.37 | 1,098,316,677.34 |
| 管理费用 | 310,225,370.77 | 207,785,069.62 | 97,646,222.96 | 411,028,277.43 |
| 研发费用 | 405,052,780.76 | 269,617,925.64 | 124,450,232.82 | 504,371,232.55 |
| 财务费用 | -131,385,735.67 | -101,307,842.22 | -50,842,630.47 | -157,469,288.89 |
| 其中:利息费用 | 17,336,958.12 | 17,278,182.51 | 6,970,541.22 | 58,545,912.74 |
| 其中:利息收入 | 166,913,113.56 | 115,157,364.09 | 59,653,354.93 | 214,764,586.07 |
| 加:公允价值变动收益 | - | 107,890.41 | 53,041.1 | -4,106,295.38 |
| 加:投资收益 | 21,502,304.43 | 21,273,000.01 | -854,709.96 | 143,207,735.65 |
| 资产处置收益 | 5,338,234.92 | 5,319,774.45 | 5,354.56 | 555,255,593.96 |
| 资产减值损失(新) | -6,423,745.23 | -5,299,408.42 | -55,747.31 | -92,979,861.26 |
| 信用减值损失(新) | -33,295,316.29 | -37,224,134.66 | -25,356,963.05 | 9,485,542.76 |
| 其他收益 | 317,209,325.12 | 178,451,529.82 | 156,252,340.07 | 115,322,327.94 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,753,251,085.08 | 1,288,049,438.08 | 777,027,606.56 | 2,893,493,871.65 |
| 加:营业外收入 | 4,124,944.65 | 2,300,876.76 | 1,264,145.27 | 3,280,974.49 |
| 减:营业外支出 | 2,230,909.83 | 1,046,686.39 | 98,186.87 | 47,940,331.36 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,755,145,119.9 | 1,289,303,628.45 | 778,193,564.96 | 2,848,834,514.78 |
| 减:所得税费用 | 221,715,279.81 | 166,409,836.28 | 117,168,438.15 | 472,362,291.11 |
| 六、净利润 | 1,533,429,840.09 | 1,122,893,792.17 | 661,025,126.81 | 2,376,472,223.67 |
| 持续经营净利润 | 1,533,429,840.09 | 1,122,893,792.17 | 661,025,126.81 | 2,376,472,223.67 |
| 归属于母公司股东的净利润 | 1,531,593,657.16 | 1,120,197,133.35 | 659,412,768.43 | 2,395,853,276.49 |
| 少数股东损益 | 1,836,182.93 | 2,696,658.82 | 1,612,358.38 | -19,381,052.82 |
| (一)基本每股收益 | 1.54 | 1.12 | 0.66 | 2.41 |
| (二)稀释每股收益 | 1.54 | 1.12 | 0.66 | 2.41 |
| 八、其他综合收益 | 3,443,387.87 | -396,233.17 | -2,952,891.55 | 8,137,393.2 |
| 归属于母公司股东的其他综合收益 | 3,561,016.34 | 142,688.72 | -2,561,026.14 | 6,714,504.51 |
| 九、综合收益总额 | 1,536,873,227.96 | 1,122,497,559 | 658,072,235.26 | 2,384,609,616.87 |
| 归属于母公司股东的综合收益总额 | 1,535,154,673.5 | 1,120,339,822.07 | 656,851,742.29 | 2,402,567,781 |
| 归属于少数股东的综合收益总额 | 1,718,554.46 | 2,157,736.93 | 1,220,492.97 | -17,958,164.13 |
| 公告日期 | 2024-10-26 | 2024-08-24 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |